Persistence of Anti-Hbs after up to 30 Years in Health Care Workers Vaccinated against Hepatitis B Virus.
HBV
anti-HBs
health care workers
vaccination
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
18
02
2021
revised:
17
03
2021
accepted:
24
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
The burden of hepatitis B virus (HBV) infection is a serious public health problem all over the world. Vaccination remains the most effective prevention measure, and safe and effective HBV vaccines have been available since 1982. Health care workers (HCWs) vaccinated against HBV and prospectively followed up for at least 14 years were classified by their antibody titers after primary vaccination as: poor responders (10-99 mIU/mL); moderate responders (100-999 mIU/mL); and good responders (≥1000 mIU/mL). The incidence of antibody loss was calculated for 1000 person-years and the anti-HBs persistence was calculated. The analysis concerned 539 HCWs: 494 good responders (91.7%); 37 moderate responders (6.9%); and eight poor responders (1.5%). The incidence of anti-HBs loss was 52.1 per 1000 person-years for the poor responders, 11.3 per 1000 person-years for the moderate responders, and 1.4 per 1000 person-years for the good responders. The mean persistence of anti-HBs differed significantly between the three groups, being: 19.2 years (95% CI: 15.6-22.8), 25.4 years (95% CI: 23.0-27.9), and 31.0 years (95% CI: 30.5-31.5) for the poor, moderate and good responders, respectively. In conclusion, our findings demonstrate a good persistence of protective anti-HBs titers in HCWs exposed to occupational risk for up to 30 years after a primary vaccination cycle (even without a booster dose) if their titer was initially higher than 100 mIU/mL.
Identifiants
pubmed: 33915763
pii: vaccines9040323
doi: 10.3390/vaccines9040323
pmc: PMC8067181
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Exp Hepatol. 2012 Dec;2(4):353-65
pubmed: 25755457
JAMA. 1985 Dec 13;254(22):3187-9
pubmed: 2933532
Hum Vaccin Immunother. 2017 Feb;13(2):440-444
pubmed: 27925503
Biomed Res Int. 2017;2017:1327492
pubmed: 29082237
Infect Dis Clin North Am. 2006 Mar;20(1):27-45
pubmed: 16527647
Sci Rep. 2016 Jun 21;6:27251
pubmed: 27324884
J Infect Dis. 2016 Jul 1;214(1):16-22
pubmed: 26802139
Pediatrics. 2014 Jun;133(6):e1500-7
pubmed: 24843060
Vaccine. 1995 Feb;13(2):139-41
pubmed: 7625106
Oman Med J. 2019 Jul;34(4):313-321
pubmed: 31360320
Jundishapur J Microbiol. 2015 Mar 21;8(3):e19579
pubmed: 25861435
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Vaccine. 2013 Mar 25;31(13):1696-700
pubmed: 23384750
BMC Infect Dis. 2015 Mar 25;15:149
pubmed: 25884719
Lancet. 2000 Feb 12;355(9203):561-5
pubmed: 10683019
JAMA. 1993 Dec 22-29;270(24):2935-9
pubmed: 8254853
Clin Infect Dis. 2015 Feb 15;60(4):505-13
pubmed: 25389254
Clin Lab. 2020 Jul 1;66(7):
pubmed: 32658415
Vaccine. 2013 Dec 17;32(1):62-8
pubmed: 24188755
Am J Prev Med. 1998 Jul;15(1):1-8
pubmed: 9651632
J Infect Dis. 1999 Jun;179(6):1319-25
pubmed: 10228050
J Occup Med Toxicol. 2015 Nov 04;10:41
pubmed: 26539242
J Infect Prev. 2020 Jan;21(1):23-27
pubmed: 32030100
MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1-33; quiz CE1-4
pubmed: 17159833
MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45
pubmed: 22108587
Int J Environ Res Public Health. 2019 Sep 09;16(18):
pubmed: 31505743
Eur J Public Health. 2011 Jun;21(3):338-43
pubmed: 20817688
Hum Vaccin Immunother. 2020;16(2):460-464
pubmed: 31487228
PLoS One. 2017 Nov 9;12(11):e0187661
pubmed: 29121107
Lancet. 2014 Dec 6;384(9959):2053-63
pubmed: 24954675
Hum Vaccin Immunother. 2017 May 4;13(5):1014-1017
pubmed: 28059607
BMC Infect Dis. 2019 May 30;19(1):482
pubmed: 31146699
Vaccine. 2004 Jan 26;22(5-6):607-10
pubmed: 14741151
Vaccine. 2011 Jun 6;29(25):4293-7
pubmed: 21419165
J Ren Care. 2014 Sep;40(3):150-6
pubmed: 24650088
J Hepatol. 1988 Apr;6(2):201-7
pubmed: 2970501